Michael Allen
Concepts (290)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psychomotor Agitation | 25 | 2017 | 70 | 4.040 |
Why?
| | Antipsychotic Agents | 23 | 2017 | 196 | 3.640 |
Why?
| | Emergency Services, Psychiatric | 16 | 2019 | 31 | 2.540 |
Why?
| | Suicide, Attempted | 23 | 2025 | 374 | 2.400 |
Why?
| | Suicidal Ideation | 15 | 2025 | 523 | 2.350 |
Why?
| | Bipolar Disorder | 24 | 2012 | 270 | 2.270 |
Why?
| | Psychotic Disorders | 11 | 2016 | 167 | 1.470 |
Why?
| | Schizophrenia | 8 | 2017 | 446 | 1.420 |
Why?
| | Emergency Service, Hospital | 17 | 2021 | 2054 | 1.420 |
Why?
| | Mental Disorders | 12 | 2017 | 1083 | 1.230 |
Why?
| | Mass Screening | 16 | 2023 | 1264 | 1.150 |
Why?
| | Suicide | 20 | 2023 | 646 | 1.100 |
Why?
| | Benzodiazepines | 9 | 2016 | 153 | 1.050 |
Why?
| | Restraint, Physical | 6 | 2016 | 72 | 1.040 |
Why?
| | Emergency Medicine | 3 | 2017 | 224 | 0.930 |
Why?
| | Aggression | 4 | 2016 | 210 | 0.830 |
Why?
| | Haloperidol | 5 | 2016 | 33 | 0.800 |
Why?
| | Risk Management | 3 | 2019 | 91 | 0.790 |
Why?
| | Antimanic Agents | 5 | 2009 | 18 | 0.780 |
Why?
| | Emergency Medical Services | 6 | 2016 | 548 | 0.720 |
Why?
| | Psychological Tests | 2 | 2017 | 139 | 0.700 |
Why?
| | Advisory Committees | 4 | 2017 | 220 | 0.700 |
Why?
| | Promethazine | 3 | 2016 | 5 | 0.690 |
Why?
| | Telephone | 2 | 2019 | 170 | 0.630 |
Why?
| | Professional-Patient Relations | 1 | 2019 | 145 | 0.590 |
Why?
| | Psychiatric Status Rating Scales | 14 | 2016 | 554 | 0.560 |
Why?
| | Loxapine | 3 | 2012 | 4 | 0.560 |
Why?
| | Lurasidone Hydrochloride | 1 | 2017 | 2 | 0.550 |
Why?
| | Medical History Taking | 2 | 2017 | 119 | 0.540 |
Why?
| | Program Development | 1 | 2019 | 366 | 0.540 |
Why?
| | Surgical Clearance | 1 | 2017 | 6 | 0.540 |
Why?
| | Risk Assessment | 11 | 2019 | 3439 | 0.510 |
Why?
| | Evidence-Based Medicine | 3 | 2017 | 746 | 0.500 |
Why?
| | Physical Examination | 2 | 2017 | 241 | 0.500 |
Why?
| | Injections, Intramuscular | 7 | 2008 | 128 | 0.500 |
Why?
| | Anticonvulsants | 2 | 2009 | 218 | 0.450 |
Why?
| | Adult | 45 | 2025 | 37818 | 0.450 |
Why?
| | Humans | 88 | 2025 | 137509 | 0.440 |
Why?
| | Communication | 1 | 2019 | 874 | 0.420 |
Why?
| | Depressive Disorder, Major | 3 | 2008 | 366 | 0.410 |
Why?
| | Lithium Carbonate | 2 | 2009 | 5 | 0.400 |
Why?
| | Psoriasis | 3 | 2023 | 102 | 0.400 |
Why?
| | Self-Injurious Behavior | 4 | 2021 | 131 | 0.400 |
Why?
| | Dibenzothiazepines | 2 | 2009 | 17 | 0.400 |
Why?
| | Depression | 4 | 2023 | 1408 | 0.380 |
Why?
| | Acute Disease | 9 | 2017 | 1008 | 0.370 |
Why?
| | Substance-Related Disorders | 6 | 2008 | 1079 | 0.370 |
Why?
| | Valproic Acid | 3 | 2006 | 47 | 0.360 |
Why?
| | Middle Aged | 30 | 2025 | 33353 | 0.350 |
Why?
| | Observation | 3 | 2009 | 52 | 0.350 |
Why?
| | Male | 44 | 2025 | 67715 | 0.340 |
Why?
| | Tranquilizing Agents | 2 | 2008 | 2 | 0.320 |
Why?
| | Female | 44 | 2025 | 73160 | 0.310 |
Why?
| | Double-Blind Method | 7 | 2025 | 1987 | 0.310 |
Why?
| | Violence | 3 | 2011 | 263 | 0.300 |
Why?
| | Nicotine | 1 | 2011 | 338 | 0.290 |
Why?
| | Comorbidity | 8 | 2019 | 1618 | 0.270 |
Why?
| | Prospective Studies | 13 | 2023 | 7598 | 0.270 |
Why?
| | Smoking | 3 | 2011 | 1639 | 0.270 |
Why?
| | Borderline Personality Disorder | 1 | 2007 | 16 | 0.260 |
Why?
| | Informed Consent | 1 | 2008 | 170 | 0.260 |
Why?
| | Disease Management | 2 | 2016 | 625 | 0.260 |
Why?
| | International Cooperation | 1 | 2007 | 198 | 0.260 |
Why?
| | Primary Health Care | 6 | 2023 | 1756 | 0.260 |
Why?
| | Risk Factors | 13 | 2023 | 10355 | 0.260 |
Why?
| | Drug Therapy, Combination | 5 | 2016 | 1060 | 0.260 |
Why?
| | Psychometrics | 4 | 2015 | 723 | 0.250 |
Why?
| | Academic Medical Centers | 2 | 2011 | 498 | 0.250 |
Why?
| | United States | 17 | 2021 | 14695 | 0.240 |
Why?
| | Guidelines as Topic | 1 | 2007 | 277 | 0.240 |
Why?
| | Alcoholism | 2 | 2015 | 805 | 0.230 |
Why?
| | Midazolam | 3 | 2016 | 56 | 0.220 |
Why?
| | Piperazines | 4 | 2007 | 351 | 0.220 |
Why?
| | Hypnotics and Sedatives | 1 | 2005 | 199 | 0.210 |
Why?
| | Motivation | 2 | 2006 | 571 | 0.210 |
Why?
| | Quality of Health Care | 1 | 2007 | 627 | 0.200 |
Why?
| | Mobile Applications | 1 | 2025 | 180 | 0.200 |
Why?
| | Young Adult | 9 | 2021 | 13241 | 0.190 |
Why?
| | Adolescent | 15 | 2021 | 21552 | 0.190 |
Why?
| | Thiazoles | 3 | 2007 | 123 | 0.190 |
Why?
| | Cost-Benefit Analysis | 3 | 2022 | 591 | 0.180 |
Why?
| | Activities of Daily Living | 1 | 2005 | 414 | 0.180 |
Why?
| | Pilot Projects | 2 | 2019 | 1703 | 0.180 |
Why?
| | Inpatients | 1 | 2025 | 502 | 0.170 |
Why?
| | Patient Satisfaction | 1 | 2005 | 656 | 0.170 |
Why?
| | Preventive Psychiatry | 1 | 2019 | 6 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2016 | 1465 | 0.160 |
Why?
| | Genome-Wide Association Study | 3 | 2023 | 1436 | 0.150 |
Why?
| | Hospitalization | 5 | 2021 | 2197 | 0.150 |
Why?
| | Schizophrenic Psychology | 2 | 2011 | 99 | 0.150 |
Why?
| | Quetiapine Fumarate | 2 | 2009 | 23 | 0.150 |
Why?
| | Lorazepam | 2 | 2016 | 27 | 0.150 |
Why?
| | Genetic Predisposition to Disease | 3 | 2015 | 2420 | 0.150 |
Why?
| | Cognition Disorders | 1 | 2003 | 517 | 0.150 |
Why?
| | Aged | 11 | 2019 | 23795 | 0.150 |
Why?
| | Health Services Research | 2 | 2013 | 402 | 0.150 |
Why?
| | Neuropsychological Tests | 1 | 2002 | 1066 | 0.140 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 3 | 2008 | 243 | 0.140 |
Why?
| | Utilization Review | 2 | 2008 | 37 | 0.140 |
Why?
| | Quality of Life | 2 | 2008 | 2869 | 0.130 |
Why?
| | Risperidone | 2 | 2007 | 29 | 0.130 |
Why?
| | Drug Administration Schedule | 2 | 2011 | 784 | 0.130 |
Why?
| | Consensus | 2 | 2017 | 685 | 0.130 |
Why?
| | Practice Guidelines as Topic | 3 | 2017 | 1580 | 0.130 |
Why?
| | Combined Modality Therapy | 4 | 2017 | 1241 | 0.130 |
Why?
| | Severity of Illness Index | 7 | 2008 | 2838 | 0.130 |
Why?
| | Antidepressive Agents, Second-Generation | 2 | 2007 | 46 | 0.130 |
Why?
| | Treatment Outcome | 8 | 2012 | 10821 | 0.130 |
Why?
| | Altitude Sickness | 1 | 2017 | 152 | 0.120 |
Why?
| | Reproducibility of Results | 4 | 2015 | 3292 | 0.120 |
Why?
| | Longitudinal Studies | 6 | 2011 | 2857 | 0.120 |
Why?
| | Patient Admission | 2 | 2008 | 191 | 0.120 |
Why?
| | Surveys and Questionnaires | 6 | 2021 | 5772 | 0.120 |
Why?
| | Antidepressive Agents | 3 | 2008 | 239 | 0.120 |
Why?
| | Aftercare | 1 | 2017 | 210 | 0.120 |
Why?
| | Quinolones | 2 | 2007 | 137 | 0.120 |
Why?
| | Administration, Inhalation | 3 | 2012 | 683 | 0.120 |
Why?
| | Referral and Consultation | 2 | 2019 | 780 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2011 | 2066 | 0.120 |
Why?
| | Multicenter Studies as Topic | 3 | 2019 | 308 | 0.120 |
Why?
| | Patient Discharge | 1 | 2021 | 895 | 0.120 |
Why?
| | Adaptor Protein Complex 1 | 1 | 2014 | 4 | 0.110 |
Why?
| | Toll-Like Receptor 3 | 1 | 2014 | 28 | 0.110 |
Why?
| | Cognition | 1 | 2022 | 1192 | 0.110 |
Why?
| | Decision Support Techniques | 1 | 2018 | 419 | 0.110 |
Why?
| | Drug Administration Routes | 1 | 2013 | 38 | 0.110 |
Why?
| | Genetic Loci | 1 | 2015 | 288 | 0.110 |
Why?
| | Crisis Intervention | 2 | 2019 | 33 | 0.110 |
Why?
| | Aged, 80 and over | 5 | 2017 | 7591 | 0.110 |
Why?
| | Altitude | 1 | 2017 | 482 | 0.100 |
Why?
| | Age of Onset | 5 | 2008 | 522 | 0.100 |
Why?
| | Military Personnel | 1 | 2019 | 543 | 0.100 |
Why?
| | Hospitals, General | 2 | 2009 | 22 | 0.090 |
Why?
| | Patient Safety | 1 | 2015 | 305 | 0.090 |
Why?
| | Safety | 3 | 2009 | 342 | 0.090 |
Why?
| | Psychiatric Department, Hospital | 1 | 2011 | 15 | 0.090 |
Why?
| | Transdermal Patch | 1 | 2011 | 15 | 0.090 |
Why?
| | Administration, Oral | 3 | 2008 | 814 | 0.090 |
Why?
| | Chronic Disease | 1 | 2017 | 1790 | 0.090 |
Why?
| | Caregivers | 2 | 2009 | 872 | 0.090 |
Why?
| | Aripiprazole | 2 | 2007 | 20 | 0.090 |
Why?
| | Aerosols | 1 | 2011 | 176 | 0.090 |
Why?
| | Time Factors | 5 | 2011 | 6817 | 0.080 |
Why?
| | Emergencies | 2 | 2010 | 164 | 0.080 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2010 | 129 | 0.080 |
Why?
| | Family Health | 2 | 2009 | 200 | 0.080 |
Why?
| | Circadian Rhythm Signaling Peptides and Proteins | 1 | 2009 | 2 | 0.080 |
Why?
| | Placebos | 2 | 2011 | 207 | 0.080 |
Why?
| | Psychiatry | 2 | 2016 | 181 | 0.080 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2010 | 54 | 0.080 |
Why?
| | Interview, Psychological | 1 | 2009 | 98 | 0.080 |
Why?
| | Affect | 2 | 2009 | 310 | 0.080 |
Why?
| | Colorado | 1 | 2019 | 4521 | 0.080 |
Why?
| | Linkage Disequilibrium | 1 | 2010 | 268 | 0.080 |
Why?
| | Diagnosis, Dual (Psychiatry) | 2 | 2006 | 36 | 0.080 |
Why?
| | Long-Term Care | 1 | 2009 | 100 | 0.080 |
Why?
| | Mental Health | 2 | 2013 | 724 | 0.080 |
Why?
| | Health Personnel | 2 | 2007 | 699 | 0.080 |
Why?
| | Health Status | 2 | 2019 | 784 | 0.070 |
Why?
| | Personality Assessment | 2 | 2006 | 84 | 0.070 |
Why?
| | Recreation | 1 | 2008 | 23 | 0.070 |
Why?
| | Internship and Residency | 2 | 2009 | 1131 | 0.070 |
Why?
| | Hospitals, Psychiatric | 1 | 2008 | 26 | 0.070 |
Why?
| | Demography | 2 | 2006 | 292 | 0.070 |
Why?
| | Age Factors | 4 | 2019 | 3299 | 0.070 |
Why?
| | Physicians | 1 | 2017 | 904 | 0.070 |
Why?
| | Brazil | 1 | 2008 | 167 | 0.070 |
Why?
| | Prevalence | 2 | 2013 | 2717 | 0.070 |
Why?
| | Depressive Disorder | 3 | 2008 | 383 | 0.070 |
Why?
| | Nervous System Diseases | 1 | 2010 | 265 | 0.070 |
Why?
| | Treatment Refusal | 1 | 2008 | 89 | 0.070 |
Why?
| | Paroxetine | 1 | 2007 | 11 | 0.070 |
Why?
| | Follow-Up Studies | 6 | 2017 | 5138 | 0.070 |
Why?
| | Quality Assurance, Health Care | 1 | 2009 | 324 | 0.070 |
Why?
| | Bupropion | 1 | 2007 | 45 | 0.070 |
Why?
| | Conscious Sedation | 1 | 2008 | 93 | 0.070 |
Why?
| | Switzerland | 1 | 2006 | 38 | 0.070 |
Why?
| | Narcotics | 1 | 2007 | 52 | 0.070 |
Why?
| | Smoking Cessation | 1 | 2011 | 447 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2008 | 1486 | 0.060 |
Why?
| | Europe | 1 | 2007 | 414 | 0.060 |
Why?
| | Health Services Misuse | 1 | 2006 | 34 | 0.060 |
Why?
| | Fluphenazine | 1 | 2006 | 5 | 0.060 |
Why?
| | Personal Satisfaction | 1 | 2008 | 211 | 0.060 |
Why?
| | Alcohol-Related Disorders | 1 | 2007 | 124 | 0.060 |
Why?
| | Bayes Theorem | 1 | 2008 | 407 | 0.060 |
Why?
| | Lithium | 1 | 2005 | 44 | 0.060 |
Why?
| | Interrupted Time Series Analysis | 2 | 2015 | 66 | 0.060 |
Why?
| | Recurrence | 2 | 2007 | 1060 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2010 | 2193 | 0.060 |
Why?
| | Curriculum | 2 | 2012 | 980 | 0.060 |
Why?
| | Cocaine-Related Disorders | 1 | 2006 | 113 | 0.060 |
Why?
| | Smartphone | 1 | 2025 | 91 | 0.060 |
Why?
| | Personality Inventory | 1 | 2005 | 142 | 0.060 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2005 | 77 | 0.060 |
Why?
| | Dangerous Behavior | 1 | 2004 | 20 | 0.050 |
Why?
| | Biomedical Research | 1 | 2010 | 689 | 0.050 |
Why?
| | Statistics as Topic | 1 | 2005 | 316 | 0.050 |
Why?
| | Urban Health Services | 1 | 2004 | 65 | 0.050 |
Why?
| | Linear Models | 1 | 2006 | 850 | 0.050 |
Why?
| | Incidence | 2 | 2011 | 2791 | 0.050 |
Why?
| | Marijuana Abuse | 1 | 2006 | 234 | 0.050 |
Why?
| | Adalimumab | 1 | 2023 | 48 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2006 | 1324 | 0.050 |
Why?
| | Serotonin | 1 | 2005 | 324 | 0.050 |
Why?
| | Sex Factors | 3 | 2019 | 2072 | 0.050 |
Why?
| | HLA-DR Antigens | 1 | 2023 | 228 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 892 | 0.050 |
Why?
| | Secondary Prevention | 2 | 2017 | 233 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2008 | 5427 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2005 | 658 | 0.050 |
Why?
| | Anxiety Disorders | 1 | 2005 | 376 | 0.050 |
Why?
| | Geriatric Assessment | 1 | 2003 | 214 | 0.040 |
Why?
| | Antibodies | 1 | 2023 | 414 | 0.040 |
Why?
| | Length of Stay | 1 | 2006 | 1210 | 0.040 |
Why?
| | Inservice Training | 1 | 2019 | 113 | 0.040 |
Why?
| | Disclosure | 1 | 2019 | 112 | 0.040 |
Why?
| | Health Status Indicators | 1 | 2019 | 171 | 0.040 |
Why?
| | Postcards as Topic | 1 | 2017 | 1 | 0.040 |
Why?
| | DNA | 1 | 2005 | 1460 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2002 | 1950 | 0.040 |
Why?
| | Rhode Island | 1 | 2017 | 27 | 0.030 |
Why?
| | Hotlines | 1 | 2017 | 32 | 0.030 |
Why?
| | Case Management | 1 | 2017 | 65 | 0.030 |
Why?
| | Substance Abuse Detection | 2 | 2009 | 90 | 0.030 |
Why?
| | Algorithms | 2 | 2019 | 1703 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2004 | 1168 | 0.030 |
Why?
| | Psychotherapy | 1 | 2017 | 164 | 0.030 |
Why?
| | Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2015 | 5 | 0.030 |
Why?
| | Cohort Studies | 4 | 2008 | 5728 | 0.030 |
Why?
| | Child | 3 | 2021 | 22034 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2016 | 179 | 0.030 |
Why?
| | Disease Progression | 1 | 2003 | 2756 | 0.030 |
Why?
| | I-kappa B Proteins | 1 | 2015 | 81 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2019 | 1286 | 0.030 |
Why?
| | Interleukin-17 | 1 | 2015 | 120 | 0.030 |
Why?
| | Research Design | 2 | 2013 | 1115 | 0.030 |
Why?
| | Outpatients | 1 | 2017 | 393 | 0.030 |
Why?
| | Logistic Models | 2 | 2012 | 2064 | 0.030 |
Why?
| | Keratinocytes | 1 | 2015 | 248 | 0.030 |
Why?
| | Models, Statistical | 1 | 2017 | 667 | 0.030 |
Why?
| | Educational Status | 1 | 2015 | 483 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2014 | 329 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 309 | 0.030 |
Why?
| | Protein Transport | 1 | 2014 | 443 | 0.020 |
Why?
| | Societies | 1 | 2012 | 40 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2015 | 429 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2015 | 949 | 0.020 |
Why?
| | Professional Competence | 1 | 2012 | 100 | 0.020 |
Why?
| | Case-Control Studies | 2 | 2010 | 3546 | 0.020 |
Why?
| | Animals | 1 | 2013 | 37009 | 0.020 |
Why?
| | Protein Conformation | 1 | 2014 | 930 | 0.020 |
Why?
| | Nuclear Proteins | 1 | 2015 | 710 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2014 | 2146 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2009 | 34 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2011 | 567 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2014 | 2901 | 0.020 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 279 | 0.020 |
Why?
| | International Classification of Diseases | 1 | 2009 | 131 | 0.020 |
Why?
| | Checklist | 1 | 2009 | 94 | 0.020 |
Why?
| | Cyclothymic Disorder | 1 | 2008 | 5 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2010 | 523 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 533 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2009 | 237 | 0.020 |
Why?
| | Cell Line | 1 | 2014 | 2852 | 0.020 |
Why?
| | Gene Frequency | 1 | 2009 | 521 | 0.020 |
Why?
| | Self Concept | 1 | 2009 | 260 | 0.020 |
Why?
| | Reference Values | 1 | 2009 | 821 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2011 | 363 | 0.020 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2007 | 12 | 0.020 |
Why?
| | Documentation | 1 | 2009 | 189 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2015 | 2838 | 0.020 |
Why?
| | Triage | 1 | 2009 | 221 | 0.020 |
Why?
| | Quality Indicators, Health Care | 1 | 2009 | 310 | 0.020 |
Why?
| | Retrospective Studies | 3 | 2009 | 15628 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2009 | 447 | 0.020 |
Why?
| | Models, Psychological | 1 | 2008 | 311 | 0.020 |
Why?
| | Circadian Rhythm | 1 | 2009 | 463 | 0.020 |
Why?
| | Brain Injuries | 1 | 2010 | 493 | 0.010 |
Why?
| | Patient Care Planning | 1 | 2005 | 155 | 0.010 |
Why?
| | Genotype | 1 | 2009 | 1920 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 2039 | 0.010 |
Why?
| | Drug Interactions | 1 | 2004 | 409 | 0.010 |
Why?
| | Forecasting | 1 | 2004 | 386 | 0.010 |
Why?
| | Drug Overdose | 1 | 2007 | 344 | 0.010 |
Why?
| | Research | 1 | 2004 | 446 | 0.010 |
Why?
| | Phenotype | 1 | 2010 | 3205 | 0.010 |
Why?
| | Alcohol Drinking | 1 | 2007 | 824 | 0.010 |
Why?
| | Critical Care | 1 | 2005 | 583 | 0.010 |
Why?
| | Pregnancy | 1 | 2010 | 6745 | 0.010 |
Why?
|
|
Allen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|